Mercurio and ACABI are working closely together to steward this exciting technology through clinical trials as well as the regulatory and reimbursement process.
-Marvin J. Slepian MD
Mercurio Biotec LLC, an Ohio company, in accordance with 31 CFR Section 515.547, has entered into a series of agreements with Heber Biotec S.A. – the commercialization arm of CIGB – the Center for Genetic Engineering and Biotechnology – Havana, to seek FDA approval for the use of Heberprot-P TM in the United States for the treatment of severe diabetic foot ulcers. This forward step advances on a prior Specific License granted by the Office of Foreign Assets Control (OFAC) of the Department of Treasury.
Mercurio Biotec LLC is an emerging Biotech company closely allied with the Arizona Center for Accelerated Biomedical Innovation – ACABI of the University of Arizona, directed by Marvin J. Slepian MD, who serves as Executive Chairman of Mercurio. “Mercurio and ACABI are working closely together to steward this exciting technology through clinical trials as well as the regulatory and reimbursement process, said Slepian”.
The regulatory approval of Heberprot-P will make this agent available in the U.S. to treat the greater than one million patients annually affected by severe diabetic foot ulcers. This agent has the potential to significantly reduce the greater than 85,000 yearly amputations performed in the United States, resulting from advanced non-healing diabetic ulcer disease, ultimately saving limbs, improving quality of life and potentially leading to billion-dollar reductions in annual U.S. healthcare costs.
Mercurio Biotec was founded by U.S. citizens with multi-year experience in the medical, pharmaceutical and legal fields and with years of experience with U.S.- Cuba relations.